Medical Economics Pulse, March 28, 2025: Major HHS restructuring, FDA device approval delays, Medicare and weight-loss medications

Hello and welcome to Medical Economics Pulse, a quick-hitting news podcast that keeps busy physicians in the know. We offer concise updates on the most important developments affecting your practice, your bottom line, and the broader health care landscape, delivered to you by our editorial team at Medical Economics.

It’s March 28, 2025, and here are today’s headlines:

The U.S. Department of Health and Human Services (HHS) recently announced plans to cut 10,000 jobs as part of a major reorganization aimed at streamlining operations and reducing costs. While the department claims the move will increase efficiency, it raises concerns about potential disruptions in health care services, regulatory oversight, and public health programs. For physicians, this could translate to longer processing times for Medicare reimbursements, slower policy updates, and administrative inefficiencies. Experts warn that fewer personnel could lead to gaps in regulatory enforcement and delayed responses to emerging health threats. For clinicians, this means staying vigilant about billing issues, policy changes, and patient access challenges that may result from the restructuring.

Next up, the U.S. Food and Drug Administration (FDA) is also reducing its workforce, which is already having a tangible impact on the review and approval process for medical devices. Physicians relying on new technologies for diagnostics, treatments, and procedures may face significant delays in accessing these innovations. This could hinder physicians’ ability to adopt cutting-edge devices that could enhance patient care and clinical outcomes. For specialists in cardiology, neurology, and surgery, where device innovation plays a critical role, this is especially concerning. Staying updated on regulatory timelines and collaborating with industry representatives will be essential to minimize disruptions in patient care.

Finally, there’s a hot-button issue gaining momentum: whether Medicare should cover weight-loss medications. A recent study found that a majority of older Americans support coverage for these treatments, citing the potential to reduce obesity-related comorbidities like diabetes and cardiovascular disease. However, the cost of weight-loss drugs remains a major sticking point. Popular medications, such as semaglutide (Wegovy), can cost more than $1,300 per month out-of-pocket. If Medicare were to cover these drugs, analysts estimate it could cost the program billions of dollars annually, sparking concerns over financial sustainability. Physicians may need to advocate for expanded coverage while helping patients navigate cost-effective weight management strategies.

And that’s it for today’s Medical Economics Pulse. Be sure to subscribe for new episodes, and read more health business news and expert content at MedicalEconomics.com. Be sure to subscribe to our premiere podcast, “Off the Chart, A Business of Medicine Podcast,” which features lively and informative conversations with health care experts, opinion leaders, and practicing physicians about the challenges facing doctors and medical practices.

Thanks for tuning in.